Provider of proprietary pharmaceuticals intended to provide novel medicines to high-margin western markets. The company's Mytesi, an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART), enabling patients to avoid the risk of potential worsening of disease due to delay of appropriate therapy.
Generating Revenue
Acquired/Merged (Operating Subsidiary)
Formerly VC-backed
The company was acquired by Jaguar Health (NASDAQ: JAGX) on July 31, 2017. The terms of the merger include additional funding for the combined company, at $0.925 per share as disclosed in the definitive joint proxy statement/prospectus.
Add a review